Abstract Number: 2461 • ACR/ARHP Annual Meeting 2018
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…Abstract Number: 2522 • ACR/ARHP Annual Meeting 2018
Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)
Background/Purpose: Clinical equivalence of BI 695501 to the adalimumab RP has been shown in pts with moderately-to-severely active RA in the Phase III VOLTAIRE®-RA study…Abstract Number: 465 • ACR/ARHP Annual Meeting 2014
18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib
Background/Purpose: Post-marketing surveillance is an important part of monitoring adverse events (AEs) following the approval of new drugs. Tofacitinib is an oral Janus kinase inhibitor…Abstract Number: 2644 • ACR/ARHP Annual Meeting 2013
Phase IB/Iia Study On Intravenous Administration Of Expanded Allogeneic Adipose-Derived Mesenchymal Stem Cells In Refractory Rheumatoid Arthritis Patients
Background/Purpose: Expanded adipose-derived stem cells (eASCs) are shown to have immune-modulatory effects both in vitro and in animal models of arthritis. eASCs are currently under…Abstract Number: 2321 • ACR/ARHP Annual Meeting 2013
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 24-Week Randomized Controlled Trial and Open-Label Extension Study
Background/Purpose: In the RAPID2 randomized controlled trial (RCT; NCT00160602), certolizumab pegol (CZP) +MTX every 2 weeks (Q2W) improved signs and symptoms of rheumatoid arthritis (RA)…Abstract Number: 2485 • ACR/ARHP Annual Meeting 2012
Tofacitinib, an Oral Janus Kinase Inhibitor: Analyses of Efficacy and Safety of 10 versus 5mg Twice Daily in a Pooled Phase 3 and Long-Term Extension Rheumatoid Arthritis Population
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. Phase (P) 3 studies demonstrated…Abstract Number: 1282 • ACR/ARHP Annual Meeting 2012
Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy in RA. Here we report the safety…
ACR Meeting Abstracts